Literature DB >> 10022532

In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery.

C M Ahmed1, B J Sugarman, D E Johnson, R E Bookstein, D P Saha, T L Nagabhushan, K N Wills.   

Abstract

A replication-deficient adenovirus encoding human interferon alpha2b, driven by the human cytomegalovirus (CMV) promoter, was constructed and characterized. This construct was used to infect human cells derived from different types of cancer. The production of protein and its secretion into the culture medium were tested by Western blotting and immunoassay. Inhibition of cell proliferation and antiviral activity, two of the most important biological activities of interferon, were observed with this construct. PC-3 cells, derived from human prostatic cancer, or Hep3B cells, derived from human hepatocellular carcinoma, were injected subcutaneously to generate and establish in vivo tumors in athymic nude mice. Intratumoral injection with the recombinant adenovirus expressing interferon alpha2b resulted in complete regression of tumor growth. Our results demonstrate that interferon gene delivery using recombinant adenoviral vectors may be a useful approach to treat a variety of cancers.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022532     DOI: 10.1089/10430349950019200

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  2 in total

Review 1.  Direct and indirect effects of IFN-α2b in malignancy treatment: not only an archer but also an arrow.

Authors:  Fei Xiong; Qi Wang; Guan-Hua Wu; Wen-Zheng Liu; Bing Wang; Yong-Jun Chen
Journal:  Biomark Res       Date:  2022-09-14

2.  Adenovirus-mediated interferon alpha gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer.

Authors:  M Ohashi; K Yoshida; M Kushida; Y Miura; S Ohnami; Y Ikarashi; Y Kitade; T Yoshida; K Aoki
Journal:  Br J Cancer       Date:  2005-08-22       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.